Skip to main content
Erschienen in: Inflammation Research 9/2020

26.06.2020 | Review

Harnessing Newton’s third-law paradigm to treat autoimmune diseases and chronic inflammations

verfasst von: Tue Gia Nguyen

Erschienen in: Inflammation Research | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

It paradoxically seems counter-intuitive to consider treatments that activate the immune systems as a method to treat autoimmune diseases and chronic inflammations when these inflammatory conditions are themselves manifested by dysregulated activations of the immune responses. However, according to Newton’s Third-Law of fundamental physics which formally states “For every action, there is an equal and opposite reaction”, it can be reasonably argued that “For every activated pro-inflammatory response, there is an opposite and intrinsic anti-inflammatory response to follow.” Therefore, harnessing these intrinsic self-regulated negative-feedbacks of anti-inflammatory and tolerogenic responses by activating the immune systems represents a novel therapeutic paradigm.

Methods

This review endeavoured to examine and discuss the current clinical and experimental evidences and therapeutic potentials of activating the innate and adaptive immune systems via their classical cell receptors, namely Toll-like receptors (TLRs), T-cell receptors (TCRs), and B cell receptors (BCRs), to modulate and suppress pathogenic inflammations.

Results

The evidence presented in this review illustrated the therapeutic potentials and the caveats of  recent approaches and advances in harnessing this unorthodox therapeutic paradigm in the treatments of autoimmune diseases, allergic and chronic inflammations. It highlighted the promising potentials of targeting BCR-activated tolergenic responses as a new approach in this new therapeutic paradigm.
Literatur
1.
Zurück zum Zitat Imanishi T, Saito T. T cell co-stimulation and functional modulation by innate signals. Trends Immunol. 2020;41:200–12.PubMed Imanishi T, Saito T. T cell co-stimulation and functional modulation by innate signals. Trends Immunol. 2020;41:200–12.PubMed
2.
Zurück zum Zitat Belardelli F, Ferrantini M. Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol. 2002;23:201–8.PubMed Belardelli F, Ferrantini M. Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol. 2002;23:201–8.PubMed
3.
4.
Zurück zum Zitat Zhao J, Yang X, Auh SL, Kim KD, Tang H, Fu YX. Do adaptive immune cells suppress or activate innate immunity? Trends Immunol. 2009;30:8–12.PubMed Zhao J, Yang X, Auh SL, Kim KD, Tang H, Fu YX. Do adaptive immune cells suppress or activate innate immunity? Trends Immunol. 2009;30:8–12.PubMed
5.
Zurück zum Zitat Foey AD, Parry SL, Williams LM, Feldmann M, Foxwell BM, Brennan FM. Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-alpha: role of the p38 and p42/44 mitogen-activated protein kinases. J Immunol. 1998;160:920–8.PubMed Foey AD, Parry SL, Williams LM, Feldmann M, Foxwell BM, Brennan FM. Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-alpha: role of the p38 and p42/44 mitogen-activated protein kinases. J Immunol. 1998;160:920–8.PubMed
6.
Zurück zum Zitat De Vos AF, Pater JM, van den Pangaart PS, de Kruif MD, van't Veer C, van der Poll T. In vivo lipopolysaccharide exposure of human blood leukocytes induces cross-tolerance to multiple TLR ligands. J Immunol. 2009;183:533–42. De Vos AF, Pater JM, van den Pangaart PS, de Kruif MD, van't Veer C, van der Poll T. In vivo lipopolysaccharide exposure of human blood leukocytes induces cross-tolerance to multiple TLR ligands. J Immunol. 2009;183:533–42.
7.
Zurück zum Zitat Higgins SC, Lavelle EC, McCann C, et al. Toll-like receptor 4-mediated innate IL-10 activates antigen-specific regulatory T cells and confers resistance to Bordetella pertussis by inhibiting inflammatory pathology. J Immunol. 2003;171:3119–277.PubMed Higgins SC, Lavelle EC, McCann C, et al. Toll-like receptor 4-mediated innate IL-10 activates antigen-specific regulatory T cells and confers resistance to Bordetella pertussis by inhibiting inflammatory pathology. J Immunol. 2003;171:3119–277.PubMed
8.
Zurück zum Zitat Bryn T, Yaqub S, Mahic M, Henjum K, Aandahl EM, Taskén K. LPS-activated monocytes suppress T-cell immune responses and induce FOXP3+ T cells through a COX-2-PGE2-dependent mechanism. Int Immunol. 2008;20:235–45.PubMed Bryn T, Yaqub S, Mahic M, Henjum K, Aandahl EM, Taskén K. LPS-activated monocytes suppress T-cell immune responses and induce FOXP3+ T cells through a COX-2-PGE2-dependent mechanism. Int Immunol. 2008;20:235–45.PubMed
9.
Zurück zum Zitat Marta M, Andersson A, Isaksson M, Kämpe O, Lobell A. Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. Eur J Immunol. 2008;38:565–75.PubMed Marta M, Andersson A, Isaksson M, Kämpe O, Lobell A. Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. Eur J Immunol. 2008;38:565–75.PubMed
10.
Zurück zum Zitat Kulkarni U, Herrmenau C, Win SJ, Bauer M, Kamradt T. IL-7 treatment augments and prolongs sepsis-induced expansion of IL-10-producing B lymphocytes and myeloid-derived suppressor cells. PLoS ONE. 2018;13:e0192304.PubMedPubMedCentral Kulkarni U, Herrmenau C, Win SJ, Bauer M, Kamradt T. IL-7 treatment augments and prolongs sepsis-induced expansion of IL-10-producing B lymphocytes and myeloid-derived suppressor cells. PLoS ONE. 2018;13:e0192304.PubMedPubMedCentral
11.
Zurück zum Zitat Zhou F, Ciric B, Zhang GX, Rostami A. Immunotherapy using lipopolysaccharide-stimulated bone marrow-derived dendritic cells to treat experimental autoimmune encephalomyelitis. Clin Exp Immunol. 2018;178:447–58. Zhou F, Ciric B, Zhang GX, Rostami A. Immunotherapy using lipopolysaccharide-stimulated bone marrow-derived dendritic cells to treat experimental autoimmune encephalomyelitis. Clin Exp Immunol. 2018;178:447–58.
12.
Zurück zum Zitat Chatenoud L, Legendre C, Ferran C, Bach JF, Kreis H. Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome–dosage and kinetics prerequisites. Transplantation. 1991;51:334–8.PubMed Chatenoud L, Legendre C, Ferran C, Bach JF, Kreis H. Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome–dosage and kinetics prerequisites. Transplantation. 1991;51:334–8.PubMed
13.
Zurück zum Zitat Herbelin A, Abramowicz D, de Groote D, et al. CD3 antibody-induced IL-10 in renal allograft recipients: an in vivo and in vitro analysis. Transplantation. 1999;68:616–22.PubMed Herbelin A, Abramowicz D, de Groote D, et al. CD3 antibody-induced IL-10 in renal allograft recipients: an in vivo and in vitro analysis. Transplantation. 1999;68:616–22.PubMed
14.
Zurück zum Zitat Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018–28.PubMed Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018–28.PubMed
15.
Zurück zum Zitat Tyrsin D, Chuvpilo S, Matskevich A, et al. From TGN1412 to TAB08: the return of CD28 superagonist therapy to clinical development for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(4 Suppl 98):45–8.PubMed Tyrsin D, Chuvpilo S, Matskevich A, et al. From TGN1412 to TAB08: the return of CD28 superagonist therapy to clinical development for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(4 Suppl 98):45–8.PubMed
16.
Zurück zum Zitat Kitazawa Y, Fujino M, Li XK, et al. Superagonist CD28 antibody preferentially expanded Foxp3-expressing nTreg cells and prevented graft-versus-host diseases. Cell Transpl. 2009;18:627–37. Kitazawa Y, Fujino M, Li XK, et al. Superagonist CD28 antibody preferentially expanded Foxp3-expressing nTreg cells and prevented graft-versus-host diseases. Cell Transpl. 2009;18:627–37.
17.
Zurück zum Zitat Christoffersson G, von Herrath M. Regulatory immune mechanisms beyond regulatory T cells. Trends Immunol. 2019;40:482–91.PubMed Christoffersson G, von Herrath M. Regulatory immune mechanisms beyond regulatory T cells. Trends Immunol. 2019;40:482–91.PubMed
18.
Zurück zum Zitat Ono S, Tsujimoto H, Hiraki S, Aosasa S. Mechanisms of sepsis-induced immunosuppression and immunological modification therapies for sepsis. Ann Gastroenterol Surg. 2018;2:351–8.PubMedPubMedCentral Ono S, Tsujimoto H, Hiraki S, Aosasa S. Mechanisms of sepsis-induced immunosuppression and immunological modification therapies for sepsis. Ann Gastroenterol Surg. 2018;2:351–8.PubMedPubMedCentral
19.
Zurück zum Zitat Jensen IJ, Sjaastad FV, Griffith TS, Badovinac VP. Sepsis-induced T cell immunoparalysis: the ins and outs of impaired T cell immunity. J Immunol. 2018;200:1543–53.PubMed Jensen IJ, Sjaastad FV, Griffith TS, Badovinac VP. Sepsis-induced T cell immunoparalysis: the ins and outs of impaired T cell immunity. J Immunol. 2018;200:1543–53.PubMed
20.
Zurück zum Zitat McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7:429–42.PubMed McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7:429–42.PubMed
21.
Zurück zum Zitat Kim EY, Moudgil KD. Immunomodulation of autoimmune arthritis by pro-inflammatory cytokines. Cytokine. 2017;98:87–96.PubMedPubMedCentral Kim EY, Moudgil KD. Immunomodulation of autoimmune arthritis by pro-inflammatory cytokines. Cytokine. 2017;98:87–96.PubMedPubMedCentral
22.
Zurück zum Zitat Willenborg DO, Fordham SA, Staykova MA, Ramshaw IA, Cowden WB. IFN-gamma is critical to the control of murine autoimmune encephalomyelitis and regulates both in the periphery and in the target tissue: a possible role for nitric oxide. J Immunol. 1999;163:5278–86.PubMed Willenborg DO, Fordham SA, Staykova MA, Ramshaw IA, Cowden WB. IFN-gamma is critical to the control of murine autoimmune encephalomyelitis and regulates both in the periphery and in the target tissue: a possible role for nitric oxide. J Immunol. 1999;163:5278–86.PubMed
23.
Zurück zum Zitat Vermeire K, Heremans H, Vandeputte M, Huang S, Billiau A, Matthys P. Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol. 1997;158:5507–13.PubMed Vermeire K, Heremans H, Vandeputte M, Huang S, Billiau A, Matthys P. Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol. 1997;158:5507–13.PubMed
24.
Zurück zum Zitat Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 2013;34:137–43.PubMed Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 2013;34:137–43.PubMed
25.
Zurück zum Zitat Kassiotis G, Kollias G. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med. 2001;193:427–34.PubMedPubMedCentral Kassiotis G, Kollias G. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med. 2001;193:427–34.PubMedPubMedCentral
26.
Zurück zum Zitat Kleijwegt FS, Laban S, Duinkerken G, et al. Critical role for TNF in the induction of human antigen-specific regulatory T cells by tolerogenic dendritic cells. J Immunol. 2010;185:1412–8.PubMed Kleijwegt FS, Laban S, Duinkerken G, et al. Critical role for TNF in the induction of human antigen-specific regulatory T cells by tolerogenic dendritic cells. J Immunol. 2010;185:1412–8.PubMed
27.
Zurück zum Zitat Housley WJ, Adams CO, Nichols FC, et al. Natural but not inducible regulatory T cells require TNF-alpha signaling for in vivo function. J Immunol. 2011;186:6779–877.PubMed Housley WJ, Adams CO, Nichols FC, et al. Natural but not inducible regulatory T cells require TNF-alpha signaling for in vivo function. J Immunol. 2011;186:6779–877.PubMed
28.
Zurück zum Zitat Zaragoza B, Chen X, Oppenheim JJ, et al. Suppressive activity of human regulatory T cells is maintained in the presence of TNF. Nat Med. 2016;22:16–7.PubMedPubMedCentral Zaragoza B, Chen X, Oppenheim JJ, et al. Suppressive activity of human regulatory T cells is maintained in the presence of TNF. Nat Med. 2016;22:16–7.PubMedPubMedCentral
29.
Zurück zum Zitat Yu Y, Yoo SM, Park HH, et al. Preconditioning with interleukin-1 beta and interferon-gamma enhances the efficacy of human umbilical cord blood-derived mesenchymal stem cells-based therapy via enhancing prostaglandin E2 secretion and indoleamine 2,3-dioxygenase activity in dextran sulfate sodium-induced colitis. J Tissue Eng Regen Med. 2019;13:1792–804.PubMed Yu Y, Yoo SM, Park HH, et al. Preconditioning with interleukin-1 beta and interferon-gamma enhances the efficacy of human umbilical cord blood-derived mesenchymal stem cells-based therapy via enhancing prostaglandin E2 secretion and indoleamine 2,3-dioxygenase activity in dextran sulfate sodium-induced colitis. J Tissue Eng Regen Med. 2019;13:1792–804.PubMed
31.
Zurück zum Zitat Prasanna SJ, Gopalakrishnan D, Shankar SR, Vasandan AB. Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS ONE. 2010;5:e9016.PubMedPubMedCentral Prasanna SJ, Gopalakrishnan D, Shankar SR, Vasandan AB. Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS ONE. 2010;5:e9016.PubMedPubMedCentral
32.
Zurück zum Zitat Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol. 2007;149:353–63.PubMedPubMedCentral Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol. 2007;149:353–63.PubMedPubMedCentral
33.
Zurück zum Zitat Lemmel EM, Brackertz D, Franke M, et al. Results of a multicenter placebo-controlled double-blind randomized phase III clinical study of treatment of rheumatoid arthritis with recombinant interferon-gamma. Rheumatol Int. 1988;8:87–93.PubMed Lemmel EM, Brackertz D, Franke M, et al. Results of a multicenter placebo-controlled double-blind randomized phase III clinical study of treatment of rheumatoid arthritis with recombinant interferon-gamma. Rheumatol Int. 1988;8:87–93.PubMed
34.
Zurück zum Zitat Cannon GW, Pincus SH, Emkey RD, et al. Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum. 2008;58(2 Suppl):S79–88.PubMed Cannon GW, Pincus SH, Emkey RD, et al. Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum. 2008;58(2 Suppl):S79–88.PubMed
35.
Zurück zum Zitat Perez-Alvarez R, Pérez-de-Lis M, Ramos-Casals M, BIOGEAS study group. Biologics-induced autoimmune diseases. Curr Opin Rheumatol. 2013;25:56–64.PubMed Perez-Alvarez R, Pérez-de-Lis M, Ramos-Casals M, BIOGEAS study group. Biologics-induced autoimmune diseases. Curr Opin Rheumatol. 2013;25:56–64.PubMed
36.
Zurück zum Zitat Her M, Kavanaugh A. Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol. 2016;137:19–27.PubMed Her M, Kavanaugh A. Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol. 2016;137:19–27.PubMed
37.
Zurück zum Zitat Lampropoulou V, Calderon-Gomez E, Roch T, et al. Suppressive functions of activated B cells in autoimmune diseases reveal the dual roles of Toll-like receptors in immunity. Immunol Rev. 2010;233:146–61.PubMed Lampropoulou V, Calderon-Gomez E, Roch T, et al. Suppressive functions of activated B cells in autoimmune diseases reveal the dual roles of Toll-like receptors in immunity. Immunol Rev. 2010;233:146–61.PubMed
38.
Zurück zum Zitat Shen P, Roch T, Lampropoulou V, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature. 2014;507:366–70.PubMedPubMedCentral Shen P, Roch T, Lampropoulou V, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature. 2014;507:366–70.PubMedPubMedCentral
39.
Zurück zum Zitat Rosser EC, Oleinika K, Tonon S, et al. Regulatory B cells are induced by gut microbiota-driven interleukin-1β and interleukin-6 production. Nat Med. 2014;20:1334–9.PubMed Rosser EC, Oleinika K, Tonon S, et al. Regulatory B cells are induced by gut microbiota-driven interleukin-1β and interleukin-6 production. Nat Med. 2014;20:1334–9.PubMed
41.
Zurück zum Zitat Wiseman AC. Immunosuppressive medications. Clin J Am Soc Nephrol. 2016;11:332–43.PubMed Wiseman AC. Immunosuppressive medications. Clin J Am Soc Nephrol. 2016;11:332–43.PubMed
43.
Zurück zum Zitat Lai Y, Dong C. Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases. Int Immunol. 2016;28:181–8.PubMed Lai Y, Dong C. Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases. Int Immunol. 2016;28:181–8.PubMed
44.
Zurück zum Zitat Fullerton JN, Gilroy DW. Resolution of inflammation: a new therapeutic frontier. Nat Rev Drug Discov. 2016;15:551–67.PubMed Fullerton JN, Gilroy DW. Resolution of inflammation: a new therapeutic frontier. Nat Rev Drug Discov. 2016;15:551–67.PubMed
45.
Zurück zum Zitat Horwitz DA, Fahmy TM, Piccirillo CA, La Cava A. Rebalancing immune homeostasis to treat autoimmune diseases. Trends Immunol. 2019;40:888–908.PubMedPubMedCentral Horwitz DA, Fahmy TM, Piccirillo CA, La Cava A. Rebalancing immune homeostasis to treat autoimmune diseases. Trends Immunol. 2019;40:888–908.PubMedPubMedCentral
46.
47.
Zurück zum Zitat Kaveri SV, Silverman GJ, Bayry J. Natural IgM in immune equilibrium and harnessing their therapeutic potential. J Immunol. 2012;88:939–45. Kaveri SV, Silverman GJ, Bayry J. Natural IgM in immune equilibrium and harnessing their therapeutic potential. J Immunol. 2012;88:939–45.
48.
Zurück zum Zitat Grönwall C, Silverman GJ. Natural IgM: beneficial autoantibodies for the control of inflammatory and autoimmune disease. J Clin Immunol. 2014;34(Suppl 1):S12–21.PubMedPubMedCentral Grönwall C, Silverman GJ. Natural IgM: beneficial autoantibodies for the control of inflammatory and autoimmune disease. J Clin Immunol. 2014;34(Suppl 1):S12–21.PubMedPubMedCentral
49.
Zurück zum Zitat Gause WC, Wynn TA, Allen JE. Type 2 immunity and wound healing: evolutionary refinement of adaptive immunity by helminths. Nat Rev Immunol. 2013;13:607–14.PubMedPubMedCentral Gause WC, Wynn TA, Allen JE. Type 2 immunity and wound healing: evolutionary refinement of adaptive immunity by helminths. Nat Rev Immunol. 2013;13:607–14.PubMedPubMedCentral
50.
Zurück zum Zitat Bashi T, Bizzaro G, Ben-Ami Shor D, Blank M, Shoenfeld Y. The mechanisms behind helminth's immunomodulation in autoimmunity. Autoimmun Rev. 2015;14:98–104.PubMed Bashi T, Bizzaro G, Ben-Ami Shor D, Blank M, Shoenfeld Y. The mechanisms behind helminth's immunomodulation in autoimmunity. Autoimmun Rev. 2015;14:98–104.PubMed
53.
Zurück zum Zitat Gao X, Ren X, Wang Q, et al. Critical roles of regulatory B and T cells in helminth parasite-induced protection against allergic airway inflammation. Clin Exp Immunol. 2019;198:390–402.PubMedPubMedCentral Gao X, Ren X, Wang Q, et al. Critical roles of regulatory B and T cells in helminth parasite-induced protection against allergic airway inflammation. Clin Exp Immunol. 2019;198:390–402.PubMedPubMedCentral
54.
Zurück zum Zitat Smallwood TB, Giacomin PR, Loukas A, Mulvenna JP, Clark RJ, Miles JJ. Helminth immunomodulation in autoimmune disease. Front Immunol. 2017;8:453.PubMedPubMedCentral Smallwood TB, Giacomin PR, Loukas A, Mulvenna JP, Clark RJ, Miles JJ. Helminth immunomodulation in autoimmune disease. Front Immunol. 2017;8:453.PubMedPubMedCentral
55.
Zurück zum Zitat Shepherd C, Navarro S, Wangchuk P, Wilson D, Daly NL, Loukas A. Identifying the immunomodulatory components of helminths. Parasite Immunol. 2015;37:293–303.PubMed Shepherd C, Navarro S, Wangchuk P, Wilson D, Daly NL, Loukas A. Identifying the immunomodulatory components of helminths. Parasite Immunol. 2015;37:293–303.PubMed
56.
Zurück zum Zitat Kahl J, Brattig N, Liebau E. The untapped pharmacopeic potential of helminths. Trends Parasitol. 2018;34:828–42.PubMed Kahl J, Brattig N, Liebau E. The untapped pharmacopeic potential of helminths. Trends Parasitol. 2018;34:828–42.PubMed
57.
Zurück zum Zitat Pearce EJ, Caspar P, Grzych JM, Lewis FA, Sher A. Downregulation of Th1 cytokine production accompanies induction of Th2 responses by a parasitic helminth, Schistosomamansoni. J Exp Med. 1991;173:159–66.PubMed Pearce EJ, Caspar P, Grzych JM, Lewis FA, Sher A. Downregulation of Th1 cytokine production accompanies induction of Th2 responses by a parasitic helminth, Schistosomamansoni. J Exp Med. 1991;173:159–66.PubMed
58.
Zurück zum Zitat Silveira AM, Gazzinelli G, Alves-Oliveira LF, et al. Human schistosomiasis mansoni: intensity of infection differentially affects the production of interleukin-10, interferon-gamma and interleukin-13 by soluble egg antigen or adult worm antigen stimulated cultures. Trans R Soc Trop Med Hyg. 2004;98:514–9.PubMed Silveira AM, Gazzinelli G, Alves-Oliveira LF, et al. Human schistosomiasis mansoni: intensity of infection differentially affects the production of interleukin-10, interferon-gamma and interleukin-13 by soluble egg antigen or adult worm antigen stimulated cultures. Trans R Soc Trop Med Hyg. 2004;98:514–9.PubMed
60.
Zurück zum Zitat Nguyen TH, Casale TB. Immune modulation for treatment of allergic disease. Immunol Rev. 2011;242:258–71.PubMed Nguyen TH, Casale TB. Immune modulation for treatment of allergic disease. Immunol Rev. 2011;242:258–71.PubMed
61.
Zurück zum Zitat van de Veen W, Akdis M. The use of biologics for immune modulation in allergic disease. J Clin Invest. 2019;130:1452–62. van de Veen W, Akdis M. The use of biologics for immune modulation in allergic disease. J Clin Invest. 2019;130:1452–62.
62.
Zurück zum Zitat Mullard A. FDA approves first peanut allergy drug. Nat Rev Drug Discov. 2020;19:156.PubMed Mullard A. FDA approves first peanut allergy drug. Nat Rev Drug Discov. 2020;19:156.PubMed
63.
Zurück zum Zitat Vickery BP, Vereda A, Casale TB, et al. AR101 Oral immunotherapy for peanut allergy. N Engl J Med. 2018;379:1991–2001.PubMed Vickery BP, Vereda A, Casale TB, et al. AR101 Oral immunotherapy for peanut allergy. N Engl J Med. 2018;379:1991–2001.PubMed
64.
Zurück zum Zitat Chu DK, Wood RA, French S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Lancet. 2019;393:2222–32.PubMed Chu DK, Wood RA, French S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Lancet. 2019;393:2222–32.PubMed
65.
Zurück zum Zitat Perkin MR. Perception of severity of adverse events in oral immunotherapy. Lancet. 2020;395:415.PubMed Perkin MR. Perception of severity of adverse events in oral immunotherapy. Lancet. 2020;395:415.PubMed
66.
Zurück zum Zitat Chinthrajah RS, Purington N, Andorf S, et al. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2019;394:1437–49.PubMedPubMedCentral Chinthrajah RS, Purington N, Andorf S, et al. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2019;394:1437–49.PubMedPubMedCentral
67.
Zurück zum Zitat Gray CL. Current controversies and future prospects for peanut allergy prevention, diagnosis and therapies. J Asthma Allergy. 2020;13:51–66.PubMedPubMedCentral Gray CL. Current controversies and future prospects for peanut allergy prevention, diagnosis and therapies. J Asthma Allergy. 2020;13:51–66.PubMedPubMedCentral
68.
Zurück zum Zitat Schülke S. Induction of interleukin-10 producing dendritic cells as a tool to suppress allergen-specific T helper 2 responses. Front Immunol. 2018;9:455.PubMedPubMedCentral Schülke S. Induction of interleukin-10 producing dendritic cells as a tool to suppress allergen-specific T helper 2 responses. Front Immunol. 2018;9:455.PubMedPubMedCentral
69.
Zurück zum Zitat Van de Veen W. The role of regulatory B cells in allergen immunotherapy. Curr Opin Allergy Clin Immunol. 2017;17:447–52.PubMed Van de Veen W. The role of regulatory B cells in allergen immunotherapy. Curr Opin Allergy Clin Immunol. 2017;17:447–52.PubMed
70.
Zurück zum Zitat Salazar F, Awuah D, Negm OH, Shakib F, Ghaemmaghami AM. The role of indoleamine 2,3-dioxygenase-aryl hydrocarbon receptor pathway in the TLR4-induced tolerogenic phenotype in human DCs. Sci Rep. 2017;7:43337.PubMedPubMedCentral Salazar F, Awuah D, Negm OH, Shakib F, Ghaemmaghami AM. The role of indoleamine 2,3-dioxygenase-aryl hydrocarbon receptor pathway in the TLR4-induced tolerogenic phenotype in human DCs. Sci Rep. 2017;7:43337.PubMedPubMedCentral
71.
Zurück zum Zitat Flórez-Grau G, Zubizarreta I, Cabezón R, Villoslada P, Benitez-Ribas D. Tolerogenic dendritic cells as a promising antigen-specific therapy in the treatment of multiple sclerosis and neuromyelitis optica from preclinical to clinical trials. Front Immunol. 2018;9:1169.PubMedPubMedCentral Flórez-Grau G, Zubizarreta I, Cabezón R, Villoslada P, Benitez-Ribas D. Tolerogenic dendritic cells as a promising antigen-specific therapy in the treatment of multiple sclerosis and neuromyelitis optica from preclinical to clinical trials. Front Immunol. 2018;9:1169.PubMedPubMedCentral
72.
Zurück zum Zitat Iberg CA, Hawiger D. Natural and induced tolerogenic dendritic cells. J Immunol. 2020;204:733–44.PubMed Iberg CA, Hawiger D. Natural and induced tolerogenic dendritic cells. J Immunol. 2020;204:733–44.PubMed
73.
Zurück zum Zitat Kuhn C, Weiner HL. Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside. Immunotherapy. 2016;8:889–906.PubMed Kuhn C, Weiner HL. Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside. Immunotherapy. 2016;8:889–906.PubMed
74.
Zurück zum Zitat Li MO, Rudensky AY. T cell receptor signalling in the control of regulatory T cell differentiation and function. Nat Rev Immunol. 2016;16:220–33.PubMedPubMedCentral Li MO, Rudensky AY. T cell receptor signalling in the control of regulatory T cell differentiation and function. Nat Rev Immunol. 2016;16:220–33.PubMedPubMedCentral
75.
Zurück zum Zitat Mikhalkevich N, Becknell B, Caligiuri MA, et al. Responsiveness of naive CD4 T cells to polarizing cytokine determines the ratio of Th1 and Th2 cell differentiation. J Immunol. 2006;176:1553–600.PubMed Mikhalkevich N, Becknell B, Caligiuri MA, et al. Responsiveness of naive CD4 T cells to polarizing cytokine determines the ratio of Th1 and Th2 cell differentiation. J Immunol. 2006;176:1553–600.PubMed
76.
Zurück zum Zitat Shen P, Fillatreau S. Antibody-independent functions of B cells: a focus on cytokines. Nat Rev Immunol. 2015;15:441–51.PubMed Shen P, Fillatreau S. Antibody-independent functions of B cells: a focus on cytokines. Nat Rev Immunol. 2015;15:441–51.PubMed
77.
Zurück zum Zitat Hussain S, Delovitch TL. Intravenous transfusion of BCR-activated B cells protects NOD mice from type 1 diabetes in an IL-10-dependent manner. J Immunol. 2007;179:7225–322.PubMed Hussain S, Delovitch TL. Intravenous transfusion of BCR-activated B cells protects NOD mice from type 1 diabetes in an IL-10-dependent manner. J Immunol. 2007;179:7225–322.PubMed
79.
Zurück zum Zitat Nguyen TG, Little CB, Yenson VM, et al. Anti-IgD antibody attenuates collagen-induced arthritis by selectively depleting mature B-cells and promoting immune tolerance. J Autoimmun. 2010;35:86–97.PubMed Nguyen TG, Little CB, Yenson VM, et al. Anti-IgD antibody attenuates collagen-induced arthritis by selectively depleting mature B-cells and promoting immune tolerance. J Autoimmun. 2010;35:86–97.PubMed
80.
Zurück zum Zitat Nguyen TG. Immune-modulation via IgD B-cell receptor suppresses allergic skin inflammation in experimental contact hypersensitivity models despite of a Th2-favoured humoral response. Immunol Lett. 2018;203:29–39.PubMed Nguyen TG. Immune-modulation via IgD B-cell receptor suppresses allergic skin inflammation in experimental contact hypersensitivity models despite of a Th2-favoured humoral response. Immunol Lett. 2018;203:29–39.PubMed
81.
Zurück zum Zitat Nguyen TG, Morris JM. Signals from activation of B-cell receptor with anti-IgD can override the stimulatory effects of excess BAFF on mature B cells in vivo. Immunol Lett. 2014;161:157–64.PubMed Nguyen TG, Morris JM. Signals from activation of B-cell receptor with anti-IgD can override the stimulatory effects of excess BAFF on mature B cells in vivo. Immunol Lett. 2014;161:157–64.PubMed
82.
Zurück zum Zitat Madan R, Demircik F, Surianarayanan S, et al. Nonredundant roles for B cell-derived IL-10 in immune counter-regulation. J Immunol. 2009;183:2312–20.PubMed Madan R, Demircik F, Surianarayanan S, et al. Nonredundant roles for B cell-derived IL-10 in immune counter-regulation. J Immunol. 2009;183:2312–20.PubMed
83.
Zurück zum Zitat Kulkarni U, Karsten CM, Kohler T, et al. IL-10 mediates plasmacytosis-associated immunodeficiency by inhibiting complement-mediated neutrophil migration. J Allergy Clin Immunol. 2016;137:1487–97.PubMed Kulkarni U, Karsten CM, Kohler T, et al. IL-10 mediates plasmacytosis-associated immunodeficiency by inhibiting complement-mediated neutrophil migration. J Allergy Clin Immunol. 2016;137:1487–97.PubMed
84.
Zurück zum Zitat Duong BH, Ota T, Aït-Azzouzene D, et al. Peripheral B cell tolerance and function in transgenic mice expressing an IgD superantigen. J Immunol. 2010;184:4143–58.PubMed Duong BH, Ota T, Aït-Azzouzene D, et al. Peripheral B cell tolerance and function in transgenic mice expressing an IgD superantigen. J Immunol. 2010;184:4143–58.PubMed
85.
Zurück zum Zitat Duong BH, Ota T, Aoki-Ota M, et al. Negative selection by IgM superantigen defines a B cell central tolerance compartment and reveals mutations allowing escape. J Immunol. 2011;187:5596–605.PubMed Duong BH, Ota T, Aoki-Ota M, et al. Negative selection by IgM superantigen defines a B cell central tolerance compartment and reveals mutations allowing escape. J Immunol. 2011;187:5596–605.PubMed
86.
Zurück zum Zitat Burnett DL, Reed JH, Christ D, Goodnow CC. Clonal redemption and clonal anergy as mechanisms to balance B cell tolerance and immunity. Immunol Rev. 2019;292:61–75.PubMed Burnett DL, Reed JH, Christ D, Goodnow CC. Clonal redemption and clonal anergy as mechanisms to balance B cell tolerance and immunity. Immunol Rev. 2019;292:61–75.PubMed
87.
Zurück zum Zitat Noorchashm H, Noorchashm N, Kern J, Rostami SY, Barker CF, Naji A. B-cells are required for the initiation of insulitis and sialitis in non-obese diabetic mice. Diabetes. 1997;46:941–6.PubMed Noorchashm H, Noorchashm N, Kern J, Rostami SY, Barker CF, Naji A. B-cells are required for the initiation of insulitis and sialitis in non-obese diabetic mice. Diabetes. 1997;46:941–6.PubMed
88.
Zurück zum Zitat Finkelman FD, Morris SC, Orekhova T, et al. Stat6 regulation of in vivo IL-4 responses. J Immunol. 2000;164:2303–10.PubMed Finkelman FD, Morris SC, Orekhova T, et al. Stat6 regulation of in vivo IL-4 responses. J Immunol. 2000;164:2303–10.PubMed
89.
Zurück zum Zitat Gause WC, Chen SJ, Greenwald RJ, et al. CD28 dependence of T cell differentiation to IL-4 production varies with the particular type 2 immune response. J Immunol. 1997;158(9):4082–7.PubMed Gause WC, Chen SJ, Greenwald RJ, et al. CD28 dependence of T cell differentiation to IL-4 production varies with the particular type 2 immune response. J Immunol. 1997;158(9):4082–7.PubMed
90.
Zurück zum Zitat Peng JK, Lin JS, Kung JT, Finkelman FD, Wu-Hsieh BA. The combined effect of IL-4 and IL-10 suppresses the generation of, but does not change the polarity of, type-1 T cells in Histoplasma infection. Int Immunol. 2005;17:193–205.PubMed Peng JK, Lin JS, Kung JT, Finkelman FD, Wu-Hsieh BA. The combined effect of IL-4 and IL-10 suppresses the generation of, but does not change the polarity of, type-1 T cells in Histoplasma infection. Int Immunol. 2005;17:193–205.PubMed
91.
Zurück zum Zitat Wohlleben G, Trujillo C, Müller J, et al. Helminth infection modulates the development of allergen-induced airway inflammation. Int Immunol. 2004;16:585–96.PubMed Wohlleben G, Trujillo C, Müller J, et al. Helminth infection modulates the development of allergen-induced airway inflammation. Int Immunol. 2004;16:585–96.PubMed
93.
Zurück zum Zitat Kamburova EG, Koenen HJ, Boon L, Hilbrands LB, Joosten I. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transpl. 2012;12:341–50. Kamburova EG, Koenen HJ, Boon L, Hilbrands LB, Joosten I. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transpl. 2012;12:341–50.
Metadaten
Titel
Harnessing Newton’s third-law paradigm to treat autoimmune diseases and chronic inflammations
verfasst von
Tue Gia Nguyen
Publikationsdatum
26.06.2020
Verlag
Springer International Publishing
Erschienen in
Inflammation Research / Ausgabe 9/2020
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-020-01374-6

Weitere Artikel der Ausgabe 9/2020

Inflammation Research 9/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.